ProMetic Life Sciences Inc.: Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
MONTREAL, QUEBEC--(Marketwire - April 23, 2008) - ProMetic Life Sciences Inc. (TSX: PLI)("ProMetic") announces that oral PBI-1402 demonstrates significant activity in patients with chemotherapy-induced anemia ("CIA"), and reduces the need for red blood cell ("RBC") transfusion.